Based on the fact that aberrant overexpression of some growth factor receptors was observed in a variety of human cancer cells, a novel nonviral gene delivery system GE7, which contains a 16-amino-acid ligand for identifying EGF receptor was constructed for tumor-targeted gene therapy. Intravenous administration of GE7 system revealed that it has the ability to target b-galactosidase (b-gal ) reporter gene into murine hepatoma (Hepa) cells. Owing to the limited antitumor effects elicited by a single-gene transfer, recent efforts to treat malignancy using combined gene therapy have been accomplished with varying degrees of success. In this study, the human cyclin-dependent kinase inhibitor gene p21 WAFÀ1 and the murine cytokine gene granulocyte-macrophage colony-stimulating factor (GM-CSF) were used simultaneously for in vivo gene therapy through systemic injection of the EGF R targeted GE7/DNA complex into murine hepatoma-bearing mice. The results demonstrated that combined administration of p21 WAFÀ1 and GM-CSF could remarkably inhibit the growth of subcutaneously transplanted hepatoma Hepa cells, and significantly increase the survival rate of tumor-bearing mice. The activities of natural killer (NK) cells and specific cytotoxic T lymphocytes (CTL) were clearly enhanced after combined gene therapy. In vitro experiments showed that p21 WAFÀ1 gene transfer exhibited a suppressive function on the growth of Hepa cells and the expression of H-2K b and B7-1 molecules on Hepa cells increased significantly after combined genes delivery. All these results suggested that the GE7 system was able to target therapeutic genes efficiently to cancer cells, which showed high EGF R expression. The cotransfer of p21 WAFÀ1 and GM-CSF genes apparently inhibited the growth of tumors through (a) the arrest of tumor cell growth and (b) the enhancement of systemic antitumor immunity.
O ne of the major obstacles in current cancer gene therapy is the lack of an effective delivery vehicle to target exogenous genes into cancer cells in vivo by systemic administration. To overcome the common disadvantages of current gene delivery systems, receptormediated gene transfer, which can potentially target the therapeutic genes into tumor cells via the overexpressed growth factor receptors has been developed as an attractive approach. The receptor-mediated gene transfer system was first described by Cheng et al, 1 who linked a2-macroglobulin to DNA by covalent modification, and the first successful gene transfer was shown by the pioneer work of Wu et al, 2 who developed the methods to introduce foreign genes into the liver via the asialoglycoprotein (ASGP) receptor. Up to now, many targeting ligands have been exploited for efficient gene transfer and endosomolytic agents [3] [4] [5] incorporated into DNA complexes have been developed to escape the enzymatic degradation induced by lysosome-endosome fusion. Particularly, the oligopeptide of influenza virus hemagglutinin was demonstrated to possess potent endosomolytic activity, either used as a free oligopeptide or a conjugated polypeptide. 6 In previous reports, a growth factor macromolecule conjugated with polylysine alone or in combination with an endosomolytic oligopeptide HA2, or a ligand oligopeptide conjugated with polylysine, have been tried with less success to target genes into cancer cells in vivo, even though they can result in a substantial augmentation of gene transfer in vitro. 6, 7 In our laboratory, a series of gene delivery systems -combinations of individual ligand oligopeptides for IGF I R, EGF R and VEGF R covalently linked to polylysine combined with an endosomolytic peptide (HA20)-polylysine, have been designed and prepared. We have examined their capability to bind plasmid DNA to form polyplexes, the mechanism of membrane entrance process and the characteristics and efficiency in transfer exogenous gene into related recep-tor-rich cells in vitro and in vivo. Results indicated that the nonviral vector of such a formulation of combinations, though resembling but not identical to the others, [8] [9] [10] could not only efficiently transfer exogenous genes into tumor cells, but also at a very low dose. [11] [12] [13] [14] According to our previous experiments, we concluded that the combined gene transfer of cyclin-dependent kinase inhibitor (p21
WAFÀ1
) and granulocyte-macrophage colony-stimulating factor (GM-CSF) using one of these systems -an EGF R ligand (16 amino acids) oligopeptide-polylysine, designated as the GE7 system, could exhibit the enhanced antitumor effect in tumor-bearing mice after peritumoral injection. 14 Here, further study revealed that promising synergistic antitumor effects based on retardation of tumor growth as well as increasing of long-term survival rate of mice could also be observed after intravenous administration of GE7 and p21 WAFÀ1 /pGM-CSF polyplex. Thus, this receptor targeted, novel gene delivery system cotransfer of a cell cycle regulator and an immunoregulator gene could exhibit great potential in cancer gene therapy.
Materials and methods

Cell line and mice
Female, 6-week-old, C57BL/6 mice (provided by SIPPR BK Experimental Animals Company, Shanghai, China) were housed for 1 week in a pathogen-free state before all experiments were conducted. The mouse hepatoma cell line (Hepa), originated from C57BL/6 mice, was obtained from the American Type Culture Collection (ATCC, Manassas, VA (CRL-1830)) and was demonstrated to have high EGF receptor expression by immunohistochemistry assay. YAC-1, a mouse lymphoma cell line was also purchased from ATCC (TIB-160). All the cell lines were maintained separately in DMEM or RPMI-1640 (GIBCO, Grand Island, NY), supplemented with 10% heat-inactived fetal calf serum, penicillin (100 U/ml), streptomycin (100 mg/ml) and amphotericin B (4 mg/ml).
Plasmid DNA and DNA preparation
The human p21 WAFÀ1 (from Dr Bert Uogelstein, Johns Hopkins University, USA), murine GM-CSF cDNA sequences obtained by RT-PCR and E. coli b-gal cDNA purchased from Promega (Madison, WI) were cloned into multiple cloning regions of the pCEP vector (provided by Dr Bert Uogelstein), respectively, yielding the recombinant clones of pCEP-p21
WAFÀ1
, pCEP-mGM-CSF and pCEP-b-gal.
Because of the intravenous utilization, all plasmid DNA samples were prepared by using QIAGEN endofree plasmid Maxi Kit (Cat. No. 12362). DNA production was monitored and an important aspect of quality control testing was to ensure the purity and potency of the final product. The purified material was required to contain o5% plasmid isoforms (linear, relaxed and denatured), B3% E. coli genomic DNA, o1% RNA, o1% protein and endotoxin levels of o0.1 EU/mg.
Preparation of GE7-poly-l-Lysine/DNA/HA20-poly-lLysine polyplex as gene delivery system An oligopeptide of 16 amino-acid GE7 (NPVVGYI-GERPQYRDL) was designed as a ligand for EGF R. HA20 (GLFEAIAEFIEGGWEGLEG) from influenza hemagglutinin was synthesized for endosomolysis and the Poly-l-Lysine (PL, Sigma, St Louis, MO) was used as a backbone for DNA binding. Synthesis of the GE7 gene delivery system and GE7-PL/DNA/HA20-PL polyplexes were performed as described in the previous literature. 14 The name of the GE7-PL/DNA/HA20-PL polyplexes used in the following transfection were abbreviated as GE7/p21 WAFÀ1 , GE7/pGM-CSF, GE7/b-gal, GE7/pCEP and GE7/p21
WAFÀ1 +pGM-CSF.
Efficacy of exogenous gene transduction mediated by GE7/b-gal complex in vivo
Hepa cells (2 Â 10 5 ) were injected subcutaneously into 6-week-old C57BL/6 female mice. For in vivo b-gal transduction, GE7/b-gal complex was injected into tail vein at a dose equivalent to 0.2 mg DNA per mouse in 100 ml normal saline when tumors were established at a size of 5 mm in diameter. At various time intervals, tumors and tissues were excised, fixed in PBS solution containing 2% formaldehyde and 0.2% glutaraldehyde for 1.5 hours at 41C. After washing with PBS for three times, they were stained with X-gal solution (1 mg/ml 5-bromo-4-chloro-3-indolyl-b-d-galactopyranoside, 5 mM K 3 (Fe(CN) 6 ), 5 mM K 4 (Fe(CN) 6 ) and 2 mM MgCl 2 ) overnight at 371C. For histological examination, stained tumors and tissues were frozen-sectioned and counterstained with neutral red.
Assay for expression of exogenous genes
To examine the production of GM-CSF in transfected Hepa cells, the supernatants of the cultured cells were collected and GM-CSF expression was measured by GM-CSF ELISA Kit (Endogen, Woburn, MA) according to the manufacturer's instructions.
Western blot analysis was carried out to examine the expression of exogenous p21 WAFÀ1 in transduced cells. Hepa cells (1-2 Â 10 5 cells/well) were seeded in T25 culture flasks and incubated at 371C with GE7/pCEP, GE7/p21 WAFÀ1 or the combined GE7/p21 WAFÀ1 and pGM-CSF for 24 hours. At 96 hours after transfection, cells were washed twice with PBS and collected by gentle scraping. Cells treated with PBS were used as control. Whole-cell lysates were subjected to Western blot analysis. Protein concentration, transfer and blocking were performed as previously described. 15 Blots were probed with 5 mg/ml monoclonal antibody against p21 WAFÀ1 (Oncogen, Cambridge, MA).
For the detection of in vivo expressed products of p21
WAFÀ1
, tumor tissues were excised from tumor-bearing mice one month after being injected i.v. with NS, GE7/ pCEP, GE7/p21
WAFÀ1 and the combination of GE7/ p21 WAFÀ1 and GM-CSF genes. The tissues were lysed by a buffered lysing solution (50 mM Tris-HCl (pH 8.0), 2% SDS, 2 mM PMSF) and the subsequent processes were performed as described above.
In vitro gene transfer of p21 WAFÀ1 in combination with pGM-CSF into Hepa cells Hepa cells were seeded onto 96-well culture plates at a density of 2 Â 10 3 per well 12-24 hours before the transfection with GE7-PL/DNA/HA20-PL complexes. After 24-hour-incubation with complexes, the medium was replaced by fresh medium. Triplicate wells of each treatment were assayed for cell viability by the CellTiter96 AQ ueous One Solution Cell Proliferation Assay (Promega, Madison, WI) at daily intervals.
Cell cycle analysis
Hepa cells were cultured in 35 mm dishes (2 Â 10 4 cells/ dish) and transfected with the GE7-PL/DNA/HA20-PL complexes as previously described. After 2 days, cells were harvested by trypsinization, washed with PBS and fixed in sodium citrate buffer. For detection of DNA content, cells were incubated in propidium iodine solution (PI, Sigma, St Louis, MO) for 30 minutes in the dark. All procedures above were performed on ice and triplicate dishes were tested in each group. Cell cycle was analyzed by FACScalibur flow cytometry software (Becton Dickinson, San Jose, CA).
Apoptosis assay
For nucleosomal DNA fragmentation analysis in transfected cells, Hepa cells (2 Â 10 3 ) were plated in 96-well plates. On the next day, cells were incubated in the presence of GE7-PL/DNA/HA20-PL complexes for 24 hours. After 48 hours, cell monolayers were washed twice with PBS. The TUNEL assay was adapted from the in situ end labeling Kit (Boehringer, Indianapolis, IN) as described in the manufacturer's protocol. The proportion of cells showing DNA fragmentation was labeled by incorporation of FITC-dUTP into DNA using terminal deoxynucleotidyltransferase followed by AP-conversion.
For Hoechst 33 258 staining, GE7-PL/DNA/HA20-PL transfected Hepa cells were fixed in 75% ethanol for 5 min at 41C. After three washes in PBS, cells were stained with Hoechst 33 258 (2 mg/ml, Sigma, St Louis, MO) for 10 minutes and rinsed with PBS. Labeled cells were examined by fluorescence microscopy.
Expression of H-2K
b and B7-1 in Hepa cells after transfection of GE7/p21 WAFÀ1 +pGM-CSF Hepa cells were plated in 35 mm dishes (2 Â 10 4 cells/dish) and were transfected with GE7-PL/DNA/HA20-PL complexes containing different plasmid DNA: GE7/ pCEP, GE7/p21 WAFÀ1 , GE7/pGM-CSF and GE7/ p21 The systemic antitumor immunity induced by combined gene therapy was investigated as follows: 3 months after treatment, tumor-free mice were rechallenged with tumorigenic doses of the parental tumor tissues. Cubes (1 mm   3 ) of tumor tissues were implanted s.c. at a single site on the opposite flank of the animals. Considering the influence of age and previously implanted tumor, 3-month-old animals, which have had tumor implanted for 1 month were used as controls. Animals, 7 weeks old, were also given the same doses of tumor tissues aiming to test the tumor generation. The development of subcutaneous tumors in animals was examined for 4 weeks.
Cytotoxic assay
Splenic lymphocytes were isolated from tumor-bearing mice 1 month after the i.v. administration of the complexes described above. Splenic lymphocytes were directly used as NK effector cells. Lymphocytes that were cocultured with inactivated Hepa cells for 7 days with 200 U recombinant IL-2 (Genzyme, Cambridge, MA) were subsequently collected as CTL effector cells. Cytotoxicity was determined by a standard 4 hours 
Statistical analysis
One-way analysis of variance (ANOVA) followed by the two-tailed Student's t-test was used for statistical evaluation of differences. Post hoc analyses were performed by using Fisher's test. Results were represented as mean7 SEM, and the statistical significance was analyzed as described in each legend of the figures and tables.
Results
GE7-PL/HA20-PL non-viral gene delivery system mediated efficient gene transfer in vivo
GE7 and HA20 were ligated to polylysine by disulfide bonds and could bind DNA by an electrostatic interaction to form a soluble complex. We tried different amounts of polypeptide GE7-PL and HA20-PL, added to a given quantity of plasmid DNA, the results showed that 1:1 was the optimal ratio of polypeptide to DNA. Electrophoresis analysis indicated that stable complexes were formed with a band trapped at the slot with no DNA migration (data not shown). It was demonstrated by immunohistochemistry that high EGF R expression could be detected in the murine Hepa hepatoma cell line and in Hepa-derived transplanted tumor tissues.
14 To examine the targetability and efficiency of the GE7 nonviral gene delivery system, we injected b-gal reporter gene with GE7 system via tail vein. The expression of the reporter gene in tumor and other tissues was examined at various times. b-gal Activity could be detected in tumor tissues as early as 3 hours after injection. It reached a maximal level at 24-48 hours post injection and gradually declined. At 2 weeks after administration, the activity of b-gal could still be found in tumor cells. No b-gal activity was observed in heart, brain, kidney and muscle tissues. Although the transient and low expression in liver, spleen and lung could be detected at 3 hours after injection, the b-gal expression could no longer be found 12 hours later in those tissues. The data suggested that the GE7 gene delivery system could target the exogenous gene to tumor tissue with high efficiency (Fig 1) .
Expression of exogenous genes in transduced tumor cells
The expression of transgene protein in Hepa cells was studied. Western blot was performed to detect p21 No reaction signal could be detected in GE7/pCEP or mock treatment groups. These data indicated that exogenous genes delivered by GE7 system could be correctly expressed.
Supernatants collected at different time-intervals from transduced cells were used to examine the level of GM-CSF production in Hepa cells. The secretion curve of murine GM-CSF showed the expression peak of GM-CSF occurred during 72-96 hours post-transduction, at a concentration of more than 20 ng/ml per 10 6 cells. No GM-CSF production was detected in p21 WAFÀ1 and pCEP treated cells (Fig 2c) .
In vitro inhibition of tumor cell growth by p21 WAFÀ1 and GM-CSF gene transfer
The effects of cotransferring p21 WAFÀ1 and GM-CSF genes on the growth of Hepa cells were assessed. When cells were transfected, respectively, with PBS, GE7/pCEP, 
GE7/p21
WAFÀ1 , GE7/pGM-CSF and the combination of p21 WAFÀ1 and GM-CSF, results showed that the treatments with PBS, GE7/pCEP and GE7/pGM-CSF did not induce the inhibition of cell growth. Obvious growth suppression was found in cells transduced with GE7/ p21 WAFÀ1 and the combination of GE7/p21 WAFÀ1 and GM-CSF. However, no significant difference was observed between the two groups presented above. On day 7, the cell-number of the group treated with PBS, GE7/ pCEP or GE7/pGM-CSF exhibited statistically significant differences (Po.01) as compared with groups treated with either GE7/p21
WAFÀ1 alone or the combination of two genes (Fig 3) . and GE7/p21 WAFÀ1 combined with GM-CSF genes while compared with the mock, vehicle control, and GE7/GM-CSF treated cells. It was implicated that S phase arrest appeared in cells overexpression of exogenous p21 WAFÀ1 (Fig 4) . (Fig 5) . All these data indicated that polypeptide GE7 system mediated p21 WAFÀ1 gene delivery induced apoptosis-related death in Hepa cells.
Induction of apoptosis in
Increased MHC I and B7-1 expression in combined gene transduced tumor cells
Flow cytometry was used to determine the expression of some immune response-related surface molecules in transduced cells. The results in Figure 6 demonstrated that cells transfected with GE7/pGM-CSF in the presence or absence of GE7/p21
WAFÀ1 could augment the expression of MHC I and B7-1 molecules on the surface of Hepa cells; however, the combined gene transfer induced a more remarkable increase in expression of these molecules. Transduction of the GE7/pCEP or GE7/p21 WAFÀ1 complexes showed no such induction effect. , GE7/pGM-CSF, and GE7/ p21 WAFÀ1 combined with pGM-CSF for 96 hours, the cells were subjected to TUNEL assay and Hoechst 33 258 fluorescence staining. Cells treated with PBS were used as control. Systemic utilization of EGF-R targeting polyplex X Liu et al Figure 7a that tumor growth was almost arrested completely in mice with the combined treatment of GE7/p21 WAFÀ1 and GM-CSF genes when compared with animals treated with NS (Po.01). The introduction of GE7/p21 WAFÀ1 or GE7/pGM-CSF alone also could result in the reduction of tumor volume in mice; however, the inhibitory effect of combined gene treatments with p21 WAFÀ1 and GM-CSF genes on tumor growth was much stronger than that of the single gene administration alone (Po.05). No obvious antitumor effects could be seen in mice treated with the GE7 vector, GE7/pCEP or plasmid DNA in this study.
Observation of the survival time of tumor-bearing mice indicated that mice receiving the combined administration of GE7/p21
WAFÀ1 and GM-CSF were able to survive much longer than all other control mice (Po.01). Data indicated that six of eight mice after combined therapy and two of eight mice after GE7/p21 WAFÀ1 injection were found to be able to survive more than 90 days, but none of the mice in the other treated groups were alive beyond 2 months (Fig 7b) .
To test whether there was any antitumoral immunity in mice that underwent various gene treatments, protection against rechallenge of wild-type tumor cells by s.c. implantation of Hepa hepatoma into opposite flanks was performed. All animals but one in control groups developed detectable subcutaneous tumors after 7 days. In contrast, only one out of six tumor-free animals receiving combined gene therapy was found to form a palpable tumor (Fig 7c) . It was suggested that a systemic antitumor immune response might be induced by combined gene therapy.
Generation of antitumor immunity in mice after combined GE7/p21
WAFÀ1 and GM-CSF gene treatment
Induction of NK or CTL activity was measured in each treatment group. Splenocytes prepared from the tumorbearing mice one month after i.v. injection were used in cytolytic assays against YAC-1 cells or Hepa cells at different effector/target ratios by a standard 4-hour 51 Cr release assay. NK cell activity assays demonstrated that splenic lymphocytes prepared from the mice treated with NS, GE7-PL/HA20-PL, GE7/pCEP and plasmid DNA showed weak NK cytotoxicity against YAC-1 cells, which displayed the failure of inducing NK activity in these groups (Fig 8a) . However, splenic cells obtained from mice treated with single or combined GE7/p21
WAFÀ1 and pGM-CSF exhibited a significant NK cell response against YAC-1 cells depending on the effector to target ratio (Po.05). The activity of CTL was tested by using Hepa cells as targets. Lymphocytes from mice treated with GE7/pGM-CSF or combination of GE7/p21 WAFÀ1 and pGM-CSF genes manifested an obvious increase of cytotoxic activity against Hepa cells. Although the CTL activities induced in mice with combined treatment were found to be higher than those in the GE7/pGM-CSF treated group, there was no statistically significant difference between the two groups. No significant CTL activity was detected in other groups of mice (Fig 8b) . These data suggested that efficient induction of both tumor-specific immunity and nonspecific immunity might contribute to the antitumor response elicited by combined gene therapy.
Discussion
It has been reported that the EGF R, which is involved in the regulation of cellular differentiation and proliferation is highly expressed in many tumor cells. 8 In light of a relation between overexpression of EGF R and the malignant diseases, EGF R has emerged as a promising target for cancer therapy. In this study, the GE7 system targeting EGF R was used as a gene delivery system and murine Hepa hepatoma with high level of EGF R expression was chosen as a therapeutic model. In our previously published paper, we have introduced the b-gal gene successfully by peritumoral injection into the tumorbearing mice using the GE7 system; no transduced product was detected in some important organs such as heart, liver, kidney, spleen and brain, but there was a high percentage of b-gal positive cells in tumor tissues. 14 However, a gene delivery system that can be applied by systemic administration would be much more useful in current cancer gene therapy. Recently, several reports have shown effective gene delivery after systemic application of transfection complexes resulting in high gene expression in the lung and lower expression in other organs. 16, 17 Intravenous administration of genes in mice mediated by PEGylated Tf-PEI/DNA complexes could result in a high expression of exogenous genes in tumor but in tail as well. 18 Here, we described the successful gene transfer into subcutaneously transplanted tumors via systemic administration of the GE7 system. Our results demonstrated that high b-gal activity could be observed in tumor tissues and the expression there persisted for more than 2 weeks. In total, 11 organs and tissues, including heart, liver, spleen, lung, kidney, brain, stomach, intestine, tail skin, testis and muscle tissue were also examined. Only a low b-gal activity at the peripheral regions of liver, spleen and lung was detected at 3 hours after injection. However, further careful examination showed that no bgal expression was then detected in brain, liver, heart, spleen, lung alveolar and pulmonary vascular endothelial cells at 12 hours after treatment. Since we have not seen bgal activity in liver kupffer cells, pulmonary vascular and alveolar cells, it seems that these virus-like GE7 complexes were not seriously trapped in the lung, or liver and spleen reticuloendothelial system. Nevertheless, we have to identify the fate of i.v.-injected GE7-polyplex, including dissociation of the complex in vivo and the outcome of dissociated polypeptide and DNA. We could not yet exclude the possibility that some of injected complexes were trapped by reticuloendothelial system and degraded, but could not be detected by b-gal assay. Such pharmacokinetic surveys are in progress as an important part of our preclinical studies right now. However, we are able to conclude here that the GE7 gene delivery system did target the exogenous gene into tumor tissues with high efficiency.
Considering that GE7 system may target exogenous genes into some normal cells, cytotoxic genes such as CD, HSV-TK, etc. would be inappropriate. As for cell cycle regulatory genes, such as CKIs, which could arrest the growth of cancer cells but have no cytotoxic effect on normal nonreplicating cells, would be preferentially and carefully chosen in our studies. Based on our extensive studies on different kinds of CKI, the p21 WAFÀ1 was proved as an effective therapeutic gene because of its strong antitumor effects and its relation with p53.
Cancer is a disease that usually consists of two faces: persistent proliferation of cancer cells and a defect in immune response from the host. The limitations of each single gene therapy approach have led researchers to Systemic utilization of EGF-R targeting polyplex X Liu et al explore combined therapies in the hope of obtaining cumulative or synergistic therapeutic effects, and recent reports indicated that combined administrations of suicide genes, cytokine genes, tumor suppressor genes could induce synergistic antitumor effects. [19] [20] [21] [22] [23] In our previous study, 14 we concluded that cotransfer of p21 WAFÀ1 and a cytokine gene GM-CSF, which was regarded as the most potent cytokine in gene therapy could synergistically elicit antitumor effects after peritumoral injection through different mechanisms: p21 WAFÀ1 , a cyclin-dependent kinase inhibitor, which arrests cell cycle progression, [24] [25] [26] was expected to reduce the growth of the tumor, whereas GM-CSF was intended to improve the host immune response against the tumor.
27-29 Further study in this paper, we observed that tumor cell growth in vitro was markedly suppressed after transduction with GE7/p21 WAFÀ1 gene and the combination of GE7/ p21 WAFÀ1 and GM-CSF genes; no significant difference was found between the two groups. Inhibitory effects on cell growth were not detected after treatment with GE7/ GM-CSF alone. So, we speculated that no direct cytotoxic effect was induced after GM-CSF gene transfer. The overall growth inhibitory effects of coexpression of the two genes were evaluated in in vivo studies which were further described here.
We have reported that apoptosis could be detected in tumor tissues after peritumoral injection of GE7/ p21 WAFÀ1 and GE7/p21 WAFÀ1 +pGM-CSF complex.
14 In this paper, we measured the DNA content in transfected cells by cell cycle analysis and the result demonstrated that the percentage of cells at S phase was higher in cells treated with GE7/p21 WAFÀ1 alone and GE7/p21 WAFÀ1 in combination with GM-CSF gene. Although p21 WAFÀ1 has been proven to arrest the cell cycle at G1 phase, 30 S phase arrest was observed in our studies. Further experiments using in situ end-labeling of fragmented DNA and fluorescent dye (Hoechst 33 258) staining indicated that the apoptosis could be detected in GE7/p21 WAFÀ1 transferred cells and GE7/ p21 WAFÀ1 +pGM-CSF cotransferred cells. We considered it probable that the GE7 oligopeptide gene delivery system contributed to the apoptosis induced by p21 WAFÀ1 gene transduction. It has been proven that apoptosis could be the result of conflicting growth control signals of the cell cycle. [31] [32] [33] As GE7 is a ligand that could active EGF R, the activation of growth receptor signal transduction pathway providing a message of cell cycle progression conflicts with the cell cycle arrest induced by p21
WAFÀ1
. The paradoxical clash of signals from opposite biological responses could trigger apoptosis. Thus, an alterative mechanism might possibly account for the apoptosis in p21 WAFÀ1 transfected cells in our system: cells continued to enter rounds of DNA synthesis in the absence of mitosis, and the uncoupling between mitosis and S phase might induce cells to culminate in polyploidy and thereby undergo apoptosis. 30 However, the assumed mechanisms of apoptosis induced by GE7-mediated p21 WAFÀ1 gene transfer remains to be further studied. The important observation in this study was the synergistic antitumor effect of p21 WAFÀ1 and GM-CSF in vivo when transduced intravenously into mice. We demonstrated here that the combined therapy using both GE7/p21 WAFÀ1 and GM-CSF could clearly inhibit the growth of tumor cells and eliminate tumor tissues more effectively than the introduction of a single gene. The numbers of surviving mice increased significantly after combined gene therapy for 3 months. Western blot analysis confirmed the expression of p21 WAFÀ1 in tumor tissues. The above results indicated that the GE7 system could target the therapeutic gene to tumor tissues and elicit the tumor suppression effects after systemic gene administration.
The reasons that cancer cells escape from the host's immune system is not only the failure of antitumor immune response of the host, but also the low immunogenicity of tumor cells. 34, 35 Expressions of MHC class I molecule and B7-1 costimulatory molecule are very important for the presentation of tumor antigen and the activation of CD8 + T cells. 36 Cao et al 37 have found that expression of MHC class I and B7-1 could be upregulated after transfection with AdCD/5-FU suicide gene combined with AdGM-CSF. In order to classify the mechanism of the synergistic effect induced by p21 WAFÀ1 and GM-CSF, we also examined cytotoxic activity of killer cells, H-K 2b (MHC class I molecule in C57BL/6) and B7-1 expression on the surface of genetransduced tumor cells. The results showed that both of H-K 2b and B7-1 expression increased significantly after combined gene therapy, which could result in the enhancement of T-cell-mediated immune response related to therapeutic efficacy. The observation is supported by the following facts from the cytotoxicity analysis. Specific cytotoxic T lymphocytes from the spleen of tumor-bearing mice treated with GE7/p21 WAFÀ1 in combination with GM-CSF exhibited an increase of cytotoxic activity against parental cells. No CTL activity against parental cells was detected in p21 WAFÀ1 -transduced mice. This result is consistent with our previously report that the expression of p21 WAFÀ1 does not lead to the improvement of tumor-specific immunity, but promotes the arrest of cell cycle progression. The enhancement of CTL activity in GM-CSF-treated mice indicated that the antitumor effect of GM-CSF is mainly dependent on the host defense mechanism, which recognized and removed the MHC I modified tumor cells. The NK activity of the splenocytes in combined gene therapy groups also increased markedly, although the results of Cao et al 37 showed no change in NK activity after combined administration of CD and GM-CSF genes. It suggested that not only tumor-specific CTL activity but also nonspecific activity contribute to the antitumor immune response. Combination gene therapy with both p21 WAFÀ1 and GM-CSF was efficacious not only in reducing tumor growth but also in establishing a systemic antitumor immune response, thereby effectively protecting against rechallenge of the wild-type tumor cells at a distant site. But classification of the antitumor immunity needed to be further studied by examining the protective effect against another type of tumor cell line.
In this paper, it can be seen that the antitumor immune response increased more significantly after combined gene therapy when compared with single gene utilization. It might be postulated that transduction of tumor cells with apoptosis-inducing gene could result in greater presentation followed by stimulating antitumor immune response; the expression of cell cycle regulatory gene p21 WAFÀ1 might promote the antitumor sensitivity induced by cytokines.
In conclusion, the study presented here indicated that the EGF receptor-mediated delivery system (GE7) has the ability to introduce therapeutic genes into target tumor tissues with overexpressed EGF receptor after systemic administration. It was encouraging that the combination of p21 WAFÀ1 and GM-CSF gene therapy could elicit synergistic tumor suppression by induction of tumor cell apoptosis after p21 WAFÀ1 gene transfer and by the efficient enhancement of antitumor immunity through GM-CSF expression.
Abbreviations EGF R, epidermal growth factor receptor; GM-CSF, granulocyte-macrophage colony-stimulating factor; CKIs, cyclin-dependent kinase inhibitors; NK, natural killer; CTL, specific cytotoxic T lymphocyte; GE7-PL, GE7-poly-l-lysine; HA20-PL, HA20-poly-l-lysine; NS, normal saline.
